OPKO Health (OPK): Shares To Trade Lower On Reimbursement Concerns - Jefferies
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Jefferies analyst, Brandon Couillard, reiterated his Hold rating on shares of Opko Health (NASDAQ: OPK) along with a price target of $10. Palmetto posted a final LCD for OPK's 4Kscore prostate cancer test that argued against Medicare coverage.
The analyst believes that Palmetto's no-coverage decision is a major setback for 4K which had been perceived as a key near term growth driver. Going one step further, the analyst thinks that Palmetto's clout in the Dx space will cause OPK's local MAC (Novitas) to follow suit.
Without Medicare, 4K's commercial pathway from here is unclear.
Shares of Opko Health closed at $10.43 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Cuts Price Target on Entergy (ETR) to $74 Following new Guidance
- NewLink Genetics (NLNK): Investor Day Focus on IDO Combos - Jefferies
- Jefferies Slashes PT, Estimates on Chipotle Mexican Grill (CMG)
Create E-mail Alert Related CategoriesAnalyst Comments
Related EntitiesJefferies & Co
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!